It is estimated that 80,000 persons in Maryland are chronically infected with hepatitis C virus (HCV). The clinical infrastructure and specialist workforce are insufficient to provide HCV treatment access to all HCV infected persons. In 2014, we developed Sharing the Cure, a provider training program and practice transformation model, with support from the CDC-funded Maryland Department of Health’s Community-based Programs to Test and Cure Hepatitis C to improve treatment access.
Sharing the Cure is composed of a one-day workshop, mini-preceptorship, and teleconference for primary care clinicians. The program runs from January-September each year. A 20 question HCV knowledge exam developed by a faculty educator and reviewed by a cohort of national faculty experts is administered at the end of each training period to certify the clinicians as HCV providers. Partner site medical staff are trained in HCV education and treatment monitoring through a lunch lecture series. Treatment outcomes have been described through July 2018.
Thirty-five primary care clinicians from eight partner sites completed the program in cohorts 1-3. Nineteen clinicians (cohort 4) are currently completing training. Thirty-two clinicians (91%) passed the exam (score ≥ 70%). Of the 3 clinicians that did not achieve a passing score, 2 passed on second attempt which included a different subset of 20 questions and 1 clinician did not pass the second exam and was denied certification. The providers have started HCV treatment in 702 individuals with treatment ongoing in 71 patients (10%), complete in 598 (85%) patients, and discontinued in 33 (5%) patients. Notably, 592 patients are currently at least 12 weeks post treatment. Of the 462 patients with virologic data reported, 449 (97%) have documented sustained virologic response/cure. Despite providers evaluating an additional 665 patients with chronic HCV infection, treatment was not started. Barriers to treatment initiation in primary care were failure to meet prior authorization criteria in 370 (56%) patients (criteria for Maryland Medicaid includes liver fibrosis of ≥ F2), lack of patient follow-up in 81 (12%) patients, and specialist referral in 73 (11%) patients.
Primary care practices can effectively be transformed into HCV treatment centers to expand HCV treatment access. However, prior authorization criteria by insurance providers remains a major barrier to HCV treatment access.